With so many rules and regulations surrounding the installation and maintenance of Biological Safety Cabinets, the Baker BSC MythBusters series looks at common laboratory myths and whether they are true or not.
Visit the BSC MythBuster page to find out more!
ApiJect is set to be the next generation in disposable injectors.
Manufacturing pre-filled injectors, these will replace multi-dose glass vials and can be mass produced to deliver vaccines and other medications globally.
Infectious disease epidemics are composed of chains of transmission, but little is known about how co-circulating transmissions vary in size.
Understanding these features could help to target interventions and track variants and their hosts with different impacts.
Did you know that there are currently 154 vaccine candidates in pre-clinical trials?
There are also 21 in Phase I trials, 12 in Phase II trials and 11 awaiting approval following Phase III trials.
The new variant of the SARS-CoV-2 virus known as the B.1.1.7 variant has a total of 23 mutations.
Six of these cause no change in the amino acids, but of the remaining 17, eight affect the spike protein. Due to this, some scientists believe the B.1.1.7 variant has a higher rate of transmissibility.
Bayer joined CureVac to support the development of the messenger RNA (mRNA) based COVID-19 vaccine.
The vaccine is now moving into its Phase III trial and plans to enroll more than 35,000 people.
Last month, NIAID announced the commencement of the Phase III trial of the Novavax investigational vaccine.
The trial will look to evaluate the effectiveness and immune response of the vaccine candidate.
A recent study revealed that UV LED lights effectively kill a human Coronavirus.
If future research finds that they are also effective against SARS-CoV-2, this technology could be an inexpensive way to disinfect hospitals and other industrial settings.
Whilst we are still living in a world largely dominated by COVID-19, here at Baker, we feel it’s important to still continue to support those who have dedicated their careers to patient and clinical care across the globe!
As vaccines programs are rolled out in many countries, the hope for a new normality is on the horizon.
At Baker, we have been #SupportingScience since 1951 and with new vaccines, therapeutics and discoveries now worldwide, we will continue to do so now more than ever!
Can overcrowding a BSC work area lead to loss of containment?
Join us for the first in our SafeGARD webinar series, hosted by Baker’s Science Director, Kara Held Ph.D., as we explore the impact of overcrowding a BSC.
Register below today to join us on 17th February.
Research has found that a genetically altered vaccine for yellow fever could protect against COVID-19.
It appears to provide protection after a single shot, whereas other SARS-CoV-2 vaccines require two doses, one month apart.
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.